AVROBIO to Share Comprehensive Gaucher Disease Program Update

Author's Avatar
Nov 17, 2022

AVROBIO%2C+Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it will host a virtual Gaucher Disease Program Update for analysts and investors on Wednesday, Dec. 7, 2022, starting at 8 am ET.